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Summary.-Eight serially transplantable human breast-cancer xenograft lines have
been established in immune-suppressed mice. Specimens from 102 primary and
secondary lesions obtained at surgery from 80 patients were implanted into mice
immune-suppressed by thymectomy and whole-body irradiation. A number of
variations of implantation site, transplantation technique, method of immune
suppression and hormonal manipulation of the host were tried in an attempt to
increase the take rate, but without success. The 8 lines established have been serially
transplanted into further immune-suppressed mice for at least 2 passages, and
appear to maintain characteristic human histopathology, chromosome number and
tumour-marker production. None ofthe tumours show hormone sensitivity. The poor
take rate may be a reflection of the biological nature of breast cancer rather than a
failure of the immune-deprivation technique, as many other human tumours grow
well as xenografts in this system.
SINCE THE SUCCESSFUL TRANSPLANTA-
TION of human tumours to immune-
suppressed rodents was first described
nearly 30 years ago (Toolan, 1951) a
variety of tumours of different histological
types have been established as transplant-
able xenograft lines in both artificially
immune-suppressed and congenitally
athymic (nude) mice. The use ofthis model
system in experimental chemotherapy and
in the study of various aspects of human
tumour biology has been described (Cobb
& Mitchley 1974; Pickard et al., 1975;,
Povlsen & Jacobsen, 1975; Steel, 1978).
Some tumour types (e.g. malignant mela-
nomas, colorectal adenocarcinomas, pan-
creatic carcinomas and bronchial car-
cinomas) are relatively easy to establish,
whereas other tumour types, including
breast carcinomas, have proved difficult
to grow (Berenbaum et al., 1974; Detre
et al., 1975; Shimosato et al., 1976). The
present report describes our attempts to
grow xenografts from patients with breast
cancer. The xenograft lines reported are
the first serially transplantable human
breast xenografts to be established and
maintained in immune-suppressed as
opposed to nude mice.
MATERIALS AND METHODS
Tumour tissue.-Fresh tumour specimens
derived from primary breast cancer, and
metastases in lymph nodes, skin and liver
were obtained at surgery. Necrotic and fatty
material was dissected from the specimens,
which were then placed in cold Ham's F12
medium with penicillin 0-25 g/l+strepto-
mycin 0 05 g/l.
Immune-suppressed mice.-The method
described here is our standard immune-
suppression technique. The modifications per-
formed in an attempt to improve the take
rate are described in the results section.
Female CBA/lac mice were immune-sup-
pressed by thymectomy at 4 weeks of age,
followed 2-4 weeks later by 9 Gy-whole-body
irradiation preceded by cytosine arabinoside
(Ara-C) 200 mg/kg i.p. 48 h before irradiation
(Steel et al., 1978). Animals were kept in a
conventional animal house, and operativeHUMAN BREAST-CANCER XENOGRAFTS IN IMMUNE-SUPPRESSED MICE
procedures were performed under ether
anaesthesia in a laminar down-flow cabinet.
Tissue implantation.-After initial dissec-
tion, selected portions of tissue were cut into
2mm cubes. Two to 4 cubes were implanted
into a deep s.c. tunnel on the ventral aspect
of each mouse, and the incision closed with a
metal clip. Mice were observed weekly for
signs of tumour growth, and when a tumour
6 mm or more in diameter arose from the
primary implant, the tumour was excised, a
specimen sent for histology, and the remain-
ing material cut into 2mm cubes- and trans-
planted into 15-20 immune-suppressed mice.
In this way, adequate tumour could be pro-
duced and stored in liquid N2 to facilitate
experiments on the same tumour passage.
RESULTS
Specimens of breast tumours from 80
patients were obtained. In some cases,
tissue from more than one site was avail-
able, so that the total number of different
specimens was 102. Each specimen was
transplanted to a number of mice at 4
sites per mouse. As can be seen from Table
I, most of the specimens were primary
TABLE I.-Take ratet in relation to source
oftumour material
Nature of
specimen p
Primary tumour
Lymph-node metastases
Cutaneous metastases
Hepatic metastases
Ascitic/pleural effusions
Total
d
spi
No.
Patients:
64
20
8
4
6
80
(102
lifferent
ecimens)
No.*
implants
2168
596
160
164
28
3116
No.
takes
7
1
0
0
0
8
* Usually 2-4 per mouse, mean = 3.
t For the purpose of this paper, a take is defined
as progressive growth of one or more implants from
a human tumour specimen, proving to be of human
origin, and capable of serial transplantation to other
mice.
breast cancer, the second commonest
tissue being lymph-node metastases. A
"take" was defined as the appearance of a
tumour at the primary implantation site,
which proved to be of human breast-
tumour origin and which gave rise to one
38
or more tumours when serially trans-
planted into further immune-suppressed
mice. Two tumours appeared to "take"
and grow in the original (man-to-mouse)
passage, but were not transplantable.
Eight transplantable xenograft lines were
established, 7 resulting from implantation
ofprimarytumours, andonefromalymph-
node metastasis. Thus the overall success
rate was 8/80 patients (10%), 8/102 speci-
mens (8%), but only 21/3116 implants
(0.7%). The take rate was too low for
statistically valid conclusions about the
comparative take rate of tumour from
different sources.
Success rates in relation to theimplanta-
tion technique are shown in Table II. Our
usual practice of s.c. implanting 2mm
cubes gave an overall take rate of 20
tumours from 2,334 implants (0.8%). One
further take arose from the implantation
of a tissue slice 0-5 x 5-0 x 5-0 mm, a take
rate of 1/216 or 0.5%. No takes were
achieved by transplantation under the
renal capsule, nor from i.m. injections of
finely minced tumour.
Recent work from this Department
(Steel et al., 1980) has shown that the
receptivity of mice to xenografted
tumours can be improved by performing
thymectomy as early as possible, and rais-
ing the level of whole-body irradiation
above the usual dose of 9 Gy. Table III
shows the results of changing the age at
thymectomy and the radiation dose.
Again, only one take was seen outside the
group given 9 Gy whole-body irradiation
after thymectomy at 4 weeks of age, and
there was no evidence for a dramatic
improvement in successful takes with this
variation in the preparation technique.
No takes were seen in the 100 nude mice
implanted with various tumours, though
one specimen (HX99) implanted in both
the nude and immune-suppressed mice
grew in the artificially immune-suppressed
hosts.
It has been shown that abrogation of
the host leucocyte response by using silica
improved the transplantation rate of rat
mammary tumours into nude mice after
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TABLE II.-Take rate in relation to mode of transplantation
Transplantation technique
2mm cubes of tumour:
s.c.
i.m.
1mm tumour cube under renal capsule
Tumour slices (0-5 x 5 0 x 5u0 mm (s.c.)
Tumour brei (i.m.)
Nude mice (2mm s.e. cubes) (irradiate(d
an(l non-irradiated)
Total
No. of No. of No. of tumours No. of lines
specimens* implants arisingt established
102
20
4
20
4
18
102
2334
260
40
216
80
186
3116
20
0
0
1
0
0
21
7
0
0
1
0
0
8
* Every specimen was implanted as s.c. cubes, and some also implanted by othier techniques.
t Some specimens yielded a "take" at only one implant, site in the first passage, but in others, tumours
occurre(l atsev-eral sites.
TABLE III.-Take rate in relation to host preparation
Immune-suppresse(l
mice
Age at thymectomy
(weeks)
4
4
3
3
Nude mice
Whiole-body
radliation (lose
(Gy)
9
10
9
10
0
4.5
Total
No. of No. of
specimens implants
102
10
6
5
18
18
102
2306
302
176
146
96
90
3116
No. of No. of lines
takes establishe(d
19
2
0
0
0
21
7
1
0
0
0
0
8
immunopotentiation (Hopper et al., 1976).
We therefore injected 25 mg of silica
particles ( < 5pm particle size) suspended
in normal saline i.p. into a group of mice
immune-suppressed by our standard tech-
nique, 2 days before, on the day of, and 3
days after tumour implantation. Ten
tumour specimens were implanted into
50 mice treated with silica and 50 mice
immune-suppressed by our standard tech-
nique alone. No tumour took in either
group. The hormonal manipulations
attempted consisted ofimplantingtumours
from premenopausal patients into mice
that received 0 25 Htg of oestrogen ben-
zoate s.c. daily for 6 weeks after trans-
plantation. Tumours from postmenopausal
women were also implanted into castrated
male mice. Tumours from 5premenopausal
and 5 postmenopausal women were im-
planted into 10 mice per specimen, half
the mice being manipulated as above, the
other half being female CBA/lac mice re-
ceiving standard immune suppression only.
One tumour (HX100) arose in 2 out of 13
implant sites in the non-hormonally
manipulated mice, and 1 out of the 15
implants in mice receiving supplementary
oestrogens. No takes were seen in the
other 9 tumours implanted. Four speci-
mens were injected as a tumour brei,
having been chopped finely with crossed
scalpels, aspirated into a syringe and
expelled repeatedly through progressively
smaller needles, until the specimen could
be injected through a 0 5mm needle. The
tumour brei was diluted 1: 9 with Ham's
F12 medium, and 25% of the resulting
volume was exposed to 100 Gy to provide
lethally irradiated cells. Each of the 4
specimens was then inoculated i.m into
the hind legs of 20 mice, with the lethally
irradiated cells added to one-third of the
total remaining volume of viable tumour
brei before injection. Thus, half of the
mice were injected with tumour brei
containing 50% lethally irradiated cells,
and the other half with 100% viable
tumour brei. No takes have been observed
in either group.
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TABLE IV.-Latent periodt, doubling time and percentage take* of xenograft lines
(1st passage (man to mouse)
<
3rd passage (2nd mouse to mouse
transplant)
Latency period Doubling time Take Latency period
Line (weeks) (days) (O%) (weeks)
99 15 22 3-1 3
100 28 18 7-1 4
101 32 70 6-7 12
102 34 36 13-3 5
103 40 26 3-8 4
104 22 20 11-4 4
105 20 17 21-4 2-5
106 26 27 4-3 6
* Number of growing tumours/number of implants x 100.
t From implantation to (levelopment of a 6mm diameter nodule.
It was noted that, in the first few weeks
after implantation, a nodule appeared at
the site of the tumour implant in 30-40%
of cases. These nodules commonly grew to
3-4 mm in diameter and then slowly
regressed. Biopsies of such nodules re-
vealed a dense region of collagen deposi-
tion, in some cases encasing clusters of
neoplastic cells. Some of these nodules
were transplanted to fresh hosts while still
growing, but no takes were obtained.
Primary xenografts appeared 15-40
weeks after implantation (Table IV). The
small number of tumours in this first
passage, and their irregularity of growth,
makes it unwise to average their growth
rates, but doubling times were 18-70 days.
By the third passage (i.e. the second pas-
sage from mouse to mouse) latent periods
after implantation were 3-12 weeks and
doubling times varied from 5 to 26 days
(Table IV).
The histology and source ofthe tumours
implanted to give rise to the xenograft
lines is as follows:
HX
No.
99 Infiltrating intra-ductal carcinoma,
Bloom and Richardson (B & R)
Grade III.
100 Infiltrating ductal carcinoma, B & R
Grade II.
101 Infiltrating ductal, Grade II.
102 Infiltrating intra-duct, Grade III.
104 Infiltrating intra-duct, Grade II.
Doubling time
(days)
8
7
14
12
8
10
5
12
Take
(%)
86
72
36
68
76
90
96
54
105 Infiltrating ductal, commedo pattern,
Grade II.
106 Infiltrating ductal, commedo pattern,
Grade III.
107 Infiltrating intraduct Grade III.
All the xenografts maintained a histo-
logical resemblance to the original tumour,
as shown by a variety of staining tech-
niques. Detailed histopathology of the
tumours will be described in another
report (Bailey et al., in preparation).
DISCUSSION
The present findings confirm previous
reports that human breast-cancer xeno-
grafts are difficult to establish. If serial
transplantation is considered a necessary
characteristic of a successful xenograft,
published take rates vary from zero
(Gershwin et al., 1977) to 1355% (Giovan-
ella et al., 1976) using nude mice. No trans-
plantable human breast-cancer xeno-
grafts have previously been reported in
artificially immune-suppressed mice, in
spite of several attempts (Detre & Gazet,
1973; Berenbaum et al., 1974). That both
the nude mouse and the immune-sup-
pressed mouse will readily accept xeno-
grafts of many other human tumours is
well known (Shimosato et al., 1976;
Stanbridge et al., 1975; Giovanella et al.,
1976).
The reasons for this difference in trans-
plantability between tumour types are
unknown, but the failure of breast cancerA5. J. BAILEY, J.-C. GAZET AND M. J. PECKHAM
to grow in recipients which are capable of
supporting other types of human malig-
nancy is itself of interest, and merits fur-
ther investigation. There are several pos-
sible explanations. Breast tumours often
contain relatively few malignant cells
encased in a dense collagenous supporting
stroma. In organ-culture systems, this
stroma appears to prevent diffusion of
nutrients and metabolites to and from the
cells, except those on the periphery of the
tissue (Heuson et al., 1975). As xenografted
tissue relies on diffusion until vascular
continuity with the host is established,
many malignant cells may die, and this
further depletion of an already small
number of malignant cells may reduce the
clonogenic cell population below that
necessary to establish a xenograft. It is
common, after xenografting, for a nodule
4-5 mm in diameter to form at the site of
implantation, and to persist for several
weeks before resolution (some workers
have considered such nodules to be posi-
tive takes). Histology of these lesions
reveals dense fibrosis with marked collagen
deposition and scattered foci of malignant
cells.
Whether the implanted tumour excites
deposition of murine collagen, perhaps
through the mediation of a fibroblast
growth factor, or whether the tumours are
capable of synthesizing collagen is not yet
known, though we are attempting to
elucidate this point. The so-called latency
of breast-tumour metastases is well recog-
nized (Allan, 1977) and it is tempting to
speculate that the appearance seen after
transplantation, and the long delay before
progressive growth ensues, relate to this
phenomenon. Wehopetoascertainwhether
tumour cells are truly dormant, perhaps
inhibited from dividing by the collagen
surrounding them, or whether the delay
can be accounted for by a slow but pro-
gressive cell division by cell-inoculation
studies.
A second possible explanation for the
poor take rate is that transplanted breast
tumours grow so slowly that they are more
vulnerable than other human tumour
types to host mechanisms which may
develop against them. Although human
breast cancer is often a very slowly grow-
ing tumour, the available data on the
growth rate of lung metastases (Steel,
1977) suggest little difference between
breast andcolonictumourdeposits, tumour
types that differ widely in their trans-
plantability. On the other hand, the
3HTd labelling index of breast carcinomas
is very low (Steel, 1977) and this may well
be a more relevant indicator ofthe growth
rate that a tumour might have on trans-
plantation.
One further possibility to account for
the poor take rate of breast tumours is the
hormone status of the host. It is known
that the levels of steroid sex hormones in
both nude and immune-suppressed mice
differ widely from those of the pre- and
postmenopausal human female (Pierpaulli
& Besedowvsky, 1975; Williams et al.,
1978). It is interesting to note that pros-
tatic cancer, the only other human cancer
convincingly shown to be hormone-
dependent, is also difficult to establish as a
xenograft (Sato et al., 1975). Attempts to
modify the hormone levels to facilitate
transplantation, by injections of oestro-
gens and progestogens, have failed to
influence the take rate in our study. Since
70%O of human breast cancer is not hor-
mone-dependent (McGuire et al., 1977) the
hormonal differences between host and
donor may not be as important as we had
believed. In this context, it is noteworthy
that in 3 ofthe 8 lines, the original tumour
was oestrogen-receptor-positive and there-
fore probably hormone-responsive (Mc-
Guire, 1977) but none of the xenografts so
far established has proved hormone-
sensitive or contained oestrogen receptors.
It is possible in these tumours that clonal
selection of the more aggressive hormone-
independent cells has caused this loss of
hormone dependence.
It is clear that unless a major improve-
ment is made in the take rate of breast-
tumour xenografts, this system will be
of no practical value for testing the
chemosensitivity ofan individual patient's
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tumour. However, if it can be shown that
human tumour xenografts maintain the
chemosensitivity of the original tumour, a
group of such xenografts should be useful
both for testing new agents for anti-breast
cancer activity and for exploring new
combinations and schedules of existing
agents. To this end, the xenografts de-
scribed here are being tested against a
variety ofsingle agents and drug combina-
tions commonly used in clinical practice
and the results ofthis study are presented
elsewhere (Bailey et al., 1980).
This work was supported by the Breast Cancer
Trust Fund.
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